JancsiTech Secures Tens of Millions in Angel Funding to Power Intelligent Radiotherapy Equipment

VCBeat has learned at the earliest opportunity that,Shenzhen Yangqi Yixin Intelligent Technology Co., Ltd.(hereinafter referred to as“Yangqi Medical”) obtained byYuanBio Venture CapitalLead Investor, Existing ShareholdersHongShan China Seed FundCo-investmentTens of millions in angel roundFinancing,Huanghe CapitalServe as the exclusive financial advisor.

The capital raised in this round will be dedicated to the research, development, and innovation of intelligent medical devices, as well as accelerating product commercialization. By deepening our expertise in nuclear medicine scenarios, we aim to provide high-precision integrated hardware-software navigation systems for radiotherapy and comprehensive smart operating room solutions. This initiative empowers medical equipment with “intelligent eyes and brains,” enabling precise control over device operations and treatment delivery, thereby enhancing therapeutic efficacy and efficiency while optimizing the patient experience.

Yangqi MedicalOn-Site Photos of Corporate Environment

Yangqi Medical was established in September 2021. Its core founding team comprises experts in nuclear medicine, nuclear physics, and artificial intelligence from prestigious institutions such as Stanford University and Alibaba Group. Focused on precision nuclear medicine, the company is building the world’s first integrated hardware-software solution for nuclear medical equipment, featuring a “radar” system and a computational brain (iSiPM).

In October 2022, to align with the company’s development strategy and business model, Yangqi Medical formally changed its corporate entity from “Hangzhou Yangqi Intelligent Technology Co., Ltd.” to “Shenzhen Yangqi Yixin Intelligent Technology Co., Ltd.,” with the English name “JancsiTech.”

Yangqi Medical empowers medical devices with technologies such as AI, high-performance distributed control systems, and multimodal sensing. By adopting an integrated hardware-software solution, it achieves real-time monitoring and control of position and dosage during radiotherapy. Committed to becoming a pioneer in the "autonomous driving" of medical equipment, Yangqi Medical leverages innovative technology to ensure that every patient receives precise and personalized diagnosis and treatment. The company has established its Qixin product series (Qishi Camera, Qiji Camera) and Qice product series (Imaging Modeling Platform, Radiation Dose Simulation Platform), serving hospital radiotherapy and radiology departments, as well as manufacturers of radiotherapy and radiological equipment.

Qice Series Products and Qice Series Products

Upholding its original aspiration to “pioneer autonomous driving for nuclear medical equipment and enable every patient to benefit from precise, personalized diagnosis and treatment,” Yangqi Medical has forged ahead with determination, ushering in a new year marked by multiple significant collaborations and advancements:

• In September 2021, the company was registered and established at Langu Science and Technology Innovation Park in Hangzhou, Zhejiang Province;

• In November 2021, the company received exclusive investment from HongShan’s Seed Fund;

• In May 2022, a technical and research collaboration agreement was formally reached with the Department of Radiology at the Diamond Bay Campus of the Second Affiliated Hospital of Dalian Medical University;

• In June 2022, we officially launched a collaboration on imaging technology with the Children's Hospital, Zhejiang University School of Medicine;

• In July 2022, invited to attend the 2022 CB Insights China Future Health Forum;

• In August 2022, officially joined the Radiotherapy Equipment Technology Branch of the China Association of Medical Equipment.

• In August 2022, officially joined the Ionizing Radiation Therapy Branch of the China Association of Medical Equipment.

• In August 2022, established an R&D collaboration with a leading domestic radiotherapy manufacturer.

Yangqi Medical has completed two rounds of financing since its establishment. Just over a month after its founding, the company secured its first round of financing, amounting to several million U.S. dollars, exclusively invested by HongShan China Seed Fund. Several months later, it closed this current round of financing. In this round, not only did the existing shareholder, HongShan China Seed Fund, continue to increase its investment, but the company also received strong support from YuanBio Venture Capital, a leading industrial investor.

Regarding this financing,Zhou Haotian, Founder of Yangqi Medicalstated: “It is a great honor to receive recognition from both new and existing investors. We will remain steadfast in increasing R&D investment in the field of precision nuclear medicine, attracting top-tier talent, and accelerating the industrialization of our products. Standardization and intelligence are undoubtedly key trends in the future development of nuclear medicine. We are committed to achieving multi-modal data fusion during therapy through software-hardware synergy, enabling comprehensive perception of target volume status and rigorous quality control throughout the treatment process. This approach enhances therapeutic efficacy and optimizes the treatment experience for patients; helps physicians better manage treatment risks and improve efficiency; and assists hospitals in streamlining treatment workflows and reducing costs. Moving forward, Yangqi Medical will continue to drive progress through the research and development of innovative nuclear medicine technologies, guided by genuine clinical needs, to provide patients with more innovative technologies, products, and services.”

Ban Bo, Partner at YuanBio Venture CapitalIt stated: “The RMB 100-billion-level nuclear medicine market is rapidly expanding under policy dividends such as population aging, domestic substitution, and large-scale infrastructure development. As the first Chinese enterprise to develop optical surface-guided radiation therapy (SGRT), Yangqi Medical chose to enter the market with functional software for nuclear medicine imaging, extending to hardware for optical SGRT and real-time intraoperative dose monitoring. Ultimately, it has become a company offering comprehensive surgical planning and navigation solutions that integrate multi-modal acquisition, monitoring, and control across multiple hardware systems, truly realizing the clinical value of ‘one improvement, two reductions, and three promotions’: improving the precision of radiotherapy; reducing the risk of radiotherapy side effects and lowering the usage threshold for physicians and medical physicists; and promoting the adoption of hypofractionated high-dose treatment regimens, adaptive dose radiotherapy planning, and patient confidence in radiotherapy. In addition, the company’s core team members all hail from renowned overseas universities, demonstrating professionalism, focus, passion, and dream-chasing spirit. Dr. Zhou Guanqun, the company’s CTO, has been engaged in nuclear physics research at the University of Science and Technology of China, the Chinese Academy of Sciences, Stanford University, and the SLAC National Accelerator Laboratory in the United States, leveraging unique ‘X-ray energy detection technology.’”’By leveraging perception and deeply integrating AI technology into diagnostic and therapeutic scenarios, supplemented by the bottleneck-breaking “accelerator control technology” to intelligently drive equipment, radiotherapy has directly advanced from an extensive stage to the era of precision radiotherapy.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 160 outstanding companies in the life and health industries, covering four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, and healthcare services. The firm has achieved substantial investment returns, with 16 of its portfolio companies having gone public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly ranked among the Top 10 venture capital funds in China’s healthcare sector and recognized as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio Venture Capital possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, the firm is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

HongShan China Seed Fund is a specialized investment fund under HongShan, focusing on angel and seed-stage investments. Since its establishment as an independent entity in 2018, the fund has strategically targeted early-stage structural innovation opportunities in technology, consumer goods, and healthcare. It has invested in over 300 early-stage startups, many of which have grown into unicorns with valuations exceeding $1 billion.

Huanghe Capital is a boutique investment bank established in late 2015, dedicated to accompanying enterprises through their long-term development. It provides refined, customized, one-stop financing services to high-quality companies in sectors such as enterprise services/technology, consumer goods, and healthcare. Additionally, leveraging a capital-market perspective, it offers critical strategic advice and support to businesses during periods of rapid growth.

To date, Huanghe Capital has completed private equity financing transactions totaling nearly RMB 10 billion for nearly 100 startups. Representative cases include: Foodism, Chatail, IvyDad, Diandi Energy, Beihai Biopharma, Haimiao Biotech, Diannei Bio-Cloud, Yunhuo Youxuan, Zaitu Business Travel, Little Bear U-Rent, Da Che Dui Zhang, and UU Paotui.